Beam Therapeutics secures standby direct license to Kobe University patents for base editing

Beam Therapeutics Inc.

Agreement dated Feb 9, 2026 among Beam, Bio Palette, and Kobe University ensures backup patent access.
If Kobe-Bio Palette license terminates (barring Beam-caused breach), Kobe grants Beam an exclusive direct license.
Beam will pay Kobe the same amounts it would have paid Bio Palette under the original sublicense.
Beam assumes prosecution and maintenance costs for Kobe patents after the effective time.
Standby license covers the same scope as Beam's current sublicense from Bio Palette.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Beam Therapeutics Inc. entered into Standby License Agreement with Kobe University and Bio Palette Co., Ltd. (effective 2026-02-09).

Action: entry
Agreement: license
Counterparty: Kobe University and Bio Palette Co., Ltd.
Effective: 2026-02-09

Exact text from the filing

on February 9, 2026, the Company entered into a standby license agreement (the “Standby License Agreement”) with Kobe and Bio Palette.

View on SEC.gov

291 material agreements filed in the last 30 days. Browse all material agreements →

Beam Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-048684

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.